This article is for all providers caring for our members
The Centers for Disease Control and Prevention (CDC) recently issued emergency use authorization (EUA) for the Novavax COVID-19 vaccine, the fourth vaccine approved to reduce the risks of the novel coronavirus, including the risk of severe illness and death.
Novavax, the first protein-based vaccine, is authorized for use in adults 18 and older who have not previously been vaccinated against COVID-19.
Novavax joins the roster of safe, effective vaccines that includes Moderna, Pfizer, and Johnson & Johnson. All four are covered by health plans, including Blue Cross Blue Shield of Massachusetts, with no out-of-pocket cost.
The CDC recommends that: